Financing channel feed – Endpoints News

Financing channel feed

After down year, 2020 brings new cash into Massachusetts biotech

5 years ago

Successful scientist-investor allies team up again — this time for a stab at rare metabolic disease

5 years ago

Billionaire Dietmar Hopp steers his secretive Covid-19 biotech player to Nasdaq following major pact with GSK

5 years ago

Another four biotechs make Wall Street debut, raising $772M+ as IPO tidal wave crests

5 years ago

Christoph Westphal bags a $170M Fund V, slated to help breed some new biotechs at Longwood

5 years ago

The outlier: 2020 may go down as one of the biggest economic meltdowns in US history — but biopharma is booming

5 years ago

'Missing link': Bayer, Morningside help catapult a new kind of delivery tech to cell and gene therapy

5 years ago

Seer raises another $55M and finally reveals proteomic tech — can it hold up?

5 years ago

Can fully shutting down the estrogen receptor make a difference in breast cancer? Olema scores $54M to find out in the clinic

5 years ago

GV's David Schenkein comes in to help mentor — and bankroll — a gene therapy 2.0 player, intrigued by their ‘science heavy’ approach to conquering severe disease

5 years ago

Elevation Oncology launches with $32.5 million Series A, gives new life to former Merrimack program

5 years ago

GSK, Germany push coronavirus-focused mRNA player CureVac's latest round to $640M

5 years ago

Amplitude raises $50M to fuel ‘emerging’ Canadian biotech field

5 years ago

Chris Garabedian's incubator leads Series A funding for gene therapy manufacturer/developer combo

5 years ago

Art Krieg’s Checkmate executes a snappy 1-2 biotech gambit — big crossover followed by an instant IPO

5 years ago

China's CRO powerhouse Tigermed to seek $1B IPO in Hong Kong — report

5 years ago

Three more biotechs tumble onto Wall Street today, raising $475M as the IPO party rocks on

5 years ago

New biotech Exalys, seeking to prevent postoperative delirium, launches with $15 million in Series A

5 years ago

A neurosurgeon spent the past 30 years developing a neoantigen tumor vaccine. Now he has $112M for a pivotal test

5 years ago

Relay reaps $400M IPO windfall after drawing the curtain on motion-based drug design pipeline

5 years ago

BioAtla rakes in $72.5M Series D, advancing research for pH-detecting cancer treatments

5 years ago

Gilead-partnered Glympse snares $46.7M for their NASH-snooping biosensors

5 years ago

'Longevity as a service': Insilico spins off AI biotech that trains deep learning on anti-aging treatments

5 years ago

Billions of dollars worth of SPACs are riding on the biotech IPO boom

5 years ago

First page Previous page 94 95 969798 99 100 Next page Last page